Ensaculin

Ensaculin
Clinical data
ATC code	none;
Pharmacokinetic data
Elimination half-life	13.7 hours
Identifiers
	IUPAC name 7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one;
CAS Number	155773-59-4 ;
PubChem CID	208923;
ChemSpider	181019 ;
UNII	869PGR00AT;
ChEMBL	ChEMBL1963107 ;
Chemical and physical data
Formula	C26H32N2O5
Molar mass	452.551 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C/4Oc3cc(OC)c(OCCCN2CCN(c1ccccc1OC)CC2)cc3\C(=C\4C)C;
	InChI InChI=1S/C26H32N2O5/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3/h5-6,8-9,16-17H,7,10-15H2,1-4H3 ; Key:FQELZLMTAPJJOL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ensaculin (KA-672) is a drug from the coumarin family, which has been researched as a potential treatment for dementia. It acts on a number of receptor systems, being both a weak NMDA antagonist and a 5HT_1A agonist. Animal studies have shown promising nootropic effects, although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic hypotension (low blood pressure).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.